λ | CI: 2.5% | CI: 97.5% | σ | Ref | Description |
---|---|---|---|---|---|
0.97 | 0.99 | 1.00 | 0.01 | hsa04724 | Glutamatergic synapse |
0.95 | 0.97 | 1.00 | 0.01 | hsa05033 | Nicotine addiction |
0.94 | 0.93 | 1.00 | 0.01 | hsa04360 | Axon guidance |
0.91 | 0.93 | 1.00 | 0.02 | hsa05414 | Dilated cardiomyopathy |
0.89 | 0.97 | 1.00 | 0.02 | hsa04931 | Insulin resistance |
0.84 | 0.88 | 0.99 | 0.03 | hsa04725 | Cholinergic synapse |
0.84 | 0.82 | 0.97 | 0.02 | hsa05032 | Morphine addiction |
0.82 | 0.78 | 0.93 | 0.02 | hsa04720 | Long-term potentiation |
0.82 | 0.76 | 0.89 | 0.02 | hsa05031 | Amphetamine addiction |
0.81 | 0.76 | 0.95 | 0.02 | hsa04912 | GnRH signaling pathway |
0.79 | 0.70 | 0.91 | 0.03 | hsa04261 | Adrenergic signaling in cardiomyocytes |
0.76 | 0.75 | 0.78 | 0.01 | hsa04727 | GABAergic synapse |
0.75 | 0.75 | 0.75 | 0.00 | hsa04080 | Neuroactive ligand-receptor interaction |
0.75 | 0.75 | 0.75 | 0.00 | hsa04723 | Retrograde endocannabinoid signaling |
0.74 | 0.75 | 0.75 | 0.00 | hsa04020 | Calcium signaling pathway |
0.74 | 0.73 | 0.76 | 0.01 | hsa04728 | Dopaminergic synapse |
0.74 | 0.76 | 0.90 | 0.03 | hsa05206 | MicroRNAs in cancer |
0.73 | 0.75 | 0.76 | 0.01 | hsa04015 | Rap1 signaling pathway |
0.71 | 0.67 | 0.95 | 0.04 | hsa04971 | Gastric acid secretion |
0.71 | 0.68 | 0.80 | 0.02 | hsa05034 | Alcoholism |